Home › Funds › Catalio Capital Management, LP › FTH
Catalio Capital Management, LP position in FTH
FAETH THERAPEUTICS INC
Catalio Capital Management, LP reported holding 14,718 shares of FTH (FAETH THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$438K, representing 0.08% of its reported portfolio and ranking #44 among its reported holdings. Catalio Capital Management, LP has disclosed FTH holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's FTH position evolved
Catalio Capital Management, LP first disclosed a stake in FTH in Q2 2025 at 14,718 shares (US$126K). The position peaked in Q1 2026 at 14,718 shares, worth US$464K. Across 6 filings, Catalio Capital Management, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 14,718 shares valued at US$438K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 14.72K | $126.28K | New |
| Q3 2025 | 14.72K | $139.09K | Hold |
| Q4 2025 | 14.72K | $157.04K | Hold |
| Q1 2026 | 14.72K | $463.91K | Hold |
| Q2 2026 | 14.72K | $367.95K | Hold |
| Q3 2026 | 14.72K | $437.71K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FTH and 13F data
FTH (FAETH THERAPEUTICS INC) is a company whose sector is not yet classified in our data. 78 other funds we track also report a position in FTH — the largest reported positions include MONTANOVA CAPITAL, LLC (US$68.7M), Avoro Capital Advisors LLC (US$41.9M), Cormorant Asset Management, LP (US$30.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FTH
- MONTANOVA CAPITAL, LLC 2.31M sh · $68.72M · Q3 2026
- Avoro Capital Advisors LLC 1.41M sh · $41.93M · Q3 2026
- Cormorant Asset Management, LP 1.03M sh · $30.58M · Q3 2026
- Trails Edge Capital Partners, LP 941.69K sh · $28.01M · Q3 2026
- Caligan Partners LP 890.21K sh · $26.47M · Q3 2026
- Vivo Capital, LLC 844.58K sh · $25.12M · Q3 2026
- BAKER BROS. ADVISORS LP 803.42K sh · $23.89M · Q3 2026
- Fairmount Funds Management LLC 722.02K sh · $21.47M · Q3 2026
- B Group, Inc. 610.17K sh · $18.15M · Q3 2026
- STEMPOINT CAPITAL LP 404.92K sh · $12.04M · Q3 2026
- Ikarian Capital, LLC 199.69K sh · $5.94M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 124.10K sh · $3.69M · Q3 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held FTH?
Catalio Capital Management, LP has disclosed FTH holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Catalio Capital Management, LP's current position in FTH?
As of Q3 2026, Catalio Capital Management, LP holds 14.72K shares of FTH (FAETH THERAPEUTICS INC), valued at $437.71K, representing 0.08% of its reported portfolio and ranking #44.
Has Catalio Capital Management, LP been buying or selling FTH?
In the latest 13F filing (Q3 2026), Catalio Capital Management, LP held unchanged its position in FTH. The position peaked in Q1 2026 at 14.72K shares.
Which other funds hold FTH?
Other major institutional holders of FTH include MONTANOVA CAPITAL, LLC, Avoro Capital Advisors LLC, Cormorant Asset Management, LP, among 78 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.